Thoratic Corp. 13D HTML

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KszoVZbQrja38putGKgVc381sdBNoweglHXFbktTwRc8FA9Biit7N5REGKRisEmI 1vkXFJ3UjrrmezZHYEjT1w== 0001021890-01-500435.txt : 20020412 0001021890-01-500435.hdr.sgml : 20020412 ACCESSION NUMBER: 0001021890-01-500435 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20011207 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: THORATEC CORP CENTRAL INDEX KEY: 0000350907 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 942340464 STATE OF INCORPORATION: CA FISCAL YEAR END: 0102 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-32553 FILM NUMBER: 1809105 BUSINESS ADDRESS: STREET 1: 6035 STONERIDGE DR CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: 9258478600 MAIL ADDRESS: STREET 1: 6035 STONERIDGE DR CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: THORATEC CARDIOSYSTEMS INC DATE OF NAME CHANGE: 20010220 FORMER COMPANY: FORMER CONFORMED NAME: THORATEC LABORATORIES CORP DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: IRELAND STAPLETON PRYOR & PASCOE PC CENTRAL INDEX KEY: 0001163231 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 1675 BROADWAY STREET 2: 26TH FL. CITY: DENVER STATE: CO ZIP: 80202 BUSINESS PHONE: 3036232700 MAIL ADDRESS: STREET 1: 1675 BROADWAY STREET 2: 26TH FL. CITY: DENVER STATE: CO ZIP: 80202 SC 13D 1 thoratic13d.htm THORATEC CORPORATION-GAMBRO 13D Thoratic Corp. 13D HTML

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                  SCHEDULE 13D
                               (Amendment No. __)
                    Under the Securities Exchange Act of 1934


                              THORATEC CORPORATION
                          ----------------------------
                                (Name of Issuer)


                      Common Stock, no par value per share
                      ------------------------------------
                         (Title of Class of Securities)


                                   885175 30 7
                                  ------------
                                 (CUSIP Number)


                                 Hardin Holmes
                    Ireland, Stapleton, Pryor & Pascoe, P.C.
               1675 Broadway, 26th Floor, Denver, Colorado 80202
                                  303.623.2700
                      -------------------------------------
                     (Name, Address and Telephone Number of
                      Person Authorized to Receive Notices
                               and Communications)


                                November 6, 2001
                     --------------------------------------
                     (Date of Event which Requires Filing of
                                 this Statement)



If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box. [ ]

NOTE:  Schedules  filed in paper format shall include a signed original and five
copies of the schedule, including  all  exhibits.  See ss.240.13d-7(b) for other
parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for  any  subsequent   amendment   containing   information  which  would  alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be “filed” for the purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

1 of 4

CUSIP No.  885175 30 7

     1.   Name of Reporting Person. S.S. or I.R.S. Identification No. of above
          persons (entities only)
          Gambro, Inc., f/k/a COBE Laboratories, Inc.
 ................................................................................
     2.   Check the Appropriate Box if a Member of a Group
          (a)
          (b)
 ................................................................................
     3.   SEC Use Only

 ................................................................................
     4.   Source of Funds:

 ................................................................................
     5.   Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
          2(d) or 2(e)

 ................................................................................
     6.   Citizenship or Place of Organization:
          State of Colorado
 ................................................................................
  Number of     7.    Sole Voting Power: 1,411,000
   Shares       ................................................................
Beneficially    8.    Shared Voting Power:  -0-
  Owned by      ................................................................
    Each        9.    Sole Dispositive Power:  1,411,000
  Reporting     ................................................................
   Person       10.   Shared Dispositive Power:  -0-
    With        ................................................................

     11.  Aggregate Amount Beneficially Owned by Each Reporting Person:
          1,411,000
 ................................................................................

     12.  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 ................................................................................

     13.  Percent of Class Represented by Amount in Row (11):
          2.6%
 ................................................................................

     14.  Type of Reporting Person
          CO
 ................................................................................

2 of 4

Item 2. Identity and Background. This statement is being filed by Gambro, Inc., f/k/a COBE Laboratories, Inc., a Colorado corporation (the “Reporting Person”). The Reporting Person’s principal office is located at 10810 W. Collins Avenue, Lakewood, CO 80215. The purpose of this Amendment is to reflect the reduction of the interest of the Reporting Person in the common stock of the Issuer to less than 5% of the outstanding shares, as a result of recent sales of shares by the Reporting Person.

Item 5. Interest in the Securities of the Issuer.

Item 5 is hereby amended and restated in its entirety as follows:

On October 1, 2001, the Reporting Person owned 3,133,076 shares of the outstanding Common Stock of the Issuer, representing 5.7% of the 55,140,000 shares outstanding. As of November 6, 2001 the Reporting Person owned 1,411,000 shares of Common Stock of the Issuer, which represents 2.6%, as a result of the following open market sales with respect to the Common Stock:


      Date                     Amount                     Price Per Share
      ----                     ------                     ---------------

    10/08/01                    6,000                           18.75
    10/09/01                   25,000                           18.0684
    10/10/01                  100,000                           18.0375
    10/11/01                    4,100                           18.15
    10/11/01                   90,900                           18.328
    10/11/01                   55,000                           18.328
    10/12/01                   80,000                           18.5
    10/15/01                   30,000                           18.5
    10/16/01                  100,000                           18.6875
    10/17/01                    5,000                           19.2
    10/18/01                   25,000                           19.0
    10/18/01                   25,000                           18.75
    10/18/01                   15,000                           19.1133
    10/19/01                   20,000                           20.5
    10/19/01                  100,000                           20.0
    10/19/01                   50,000                           19.25
    10/19/01                   35,000                           21.0
    10/22/01                   25,000                           20.75
    10/23/01                   80,000                           20.56255
    10/24/01                   40,000                           19.25
    10/24/01                   50,000                           19.0
    10/24/01                  100,000                           18.25

3 of 4


    10/25/01                    50,000                          19.5
    10/25/01                   100,000                          19.0
    10/26/01                    40,000                          19.5
    10/31/01                    30,000                          19.5
    10/31/01                    50,000                          19.21
    10/31/01                    50,000                          19.2
    11/01/01                    27,500                          19.57277
    11/05/01                     2,500                          19.85

After reasonable inquiry and to my best knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

                                        GAMBRO, INC.



November 9, 2001                        By:   /s/ Kevin Smith
- ----------------                           -----------------------------------
     Date                                  Kevin Smith, President

4 of 4

-----END PRIVACY-ENHANCED MESSAGE-----